SEOUL, SOUTH KOREA, February 5, 2024 /EINPresswire.com/ -- Deep Bio, a pioneer of AI-powered cancer diagnostics solutions, proudly announced the inclusion of DeepDx Prostate in CancerX's Solutions Catalog. This significant participation...

Deep Bio: An artificial intelligence-based prostate cancer diagnosis aid developed by a Korean company has received marketing authorization from overseas regulators, attracting the industry’s attention. Deep Bio said Tuesday that its...

Invitation from Deep Bio: Our team is ready to greet you at booth #3445! Find out how DeepDx® Prostate empowers pathologists. Also, Deep Bio will present two research abstracts in relation to biomarker in prostate and breast cancers at...

Deep Bio: USCAP 2023 is sixth consecutive year of presenting research abstracts  SEOUL, SOUTH KOREA (PRWEB) MARCH 14, 2023 - Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software shared three...

Dive Deeper into Data-Driven Pathology at USCAP 2023 with DeepBio. USCAP 2023, find us at booth #349 to learn more about our flagship product DeepDx® Prostate, among others, and what values they bring to pathology. Moreover, don't miss...

Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the...